Distinctive features of female-to-male transsexualism and prevalence of gender identity disorder in japan

Journal of Sexual Medicine

Volumn 8, Issue 6, 2011, Pages 1686-1693

  Baba, Tsuyoshi ^a   Endo, Toshiaki ^a   Ikeda, Keiko ^a   Shimizu, Ayumi ^a   Honnma, Hiroyuki ^b   Ikeda, Hiroshi ^a,c   Masumori, Naoya ^a   Ohmura, Tousei ^a   Kiya, Tamotsu ^d   Fujimoto, Takashi ^e   Koizumi, Motoiki ^f   Saito, Tsuyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b Asada Ladies Clinic   (Japan)

^c HOKKAIDO BUNKYO UNIVERSITY   (Japan)

^d Ena Ladies Clinic   (Japan)

^e Kamiya Ladies Clinic   (Japan)

^f Central Women's Clinic   (Japan)

Author keywords

Adiponectin; Female to Male Transsexualism; Gender Identity Disorder; Insulin Resistance; Polycystic Ovary Syndrome

Indexed keywords

ANDROGEN; INSULIN;

ADULT; ARTICLE; FEMALE TO MALE TRANSSEXUAL; GENDER IDENTITY DISORDER; HEALTH CARE; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; JAPAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MENSTRUAL CYCLE; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; TRANSRECTAL ULTRASONOGRAPHY; TRANSVAGINAL ECHOGRAPHY;

EID: 79957908270     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02252.x     Document Type: Article

References (41)

1. De Cuypere G, Van Hemelrijck M, Michel A, Carael B, Heylens G, Rubens R, Hoebeke P, Monstrey S. Prevalence and demography of transsexualism in Belgium. Eur Psychiatry 2007;22:137-41.
2. The Rotterdam ESHERE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:41-7.
3. The Rotterdam ESHERE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
5. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG. Cardiometabolic risk in polycystic ovary syndrome: A comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008;23:2352-8.
6. Balen AH, Schachter ME, Montgomery D, Reid RW, Jacobs HS. Polycystic ovaries are a common finding in untreated female to male transsexuals. Clin Endocrinol (Oxf) 1993;38:325-9.
7. Bosinski HA, Peter M, Bonatz G, Arndt R, Heidenreich M, Sippell WG, Wille R. A higher rate of hyperandrogenic disorders in female-to-male transsexuals. Psychoneuroendocrinology 1997;22:361-80.
8. Baba T, Endo T, Honnma H, Kitajima Y, Hayashi T, Ikeda H, Masumori N, Kamiya H, Moriwaka O, Saito T. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod 2007;22:1011-6.
9. Mueller A, Gooren LJ, Naton-Schotz S, Cupisti S. Prevalence of polycystic ovary syndrome and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 2008;93:1408-11.
10. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
11. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
12. Futterweit W. Polycystic ovary syndrome: Clinical perspectives and management. Obstet Gynecol Surv 1999;54:403-13.
13. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
14. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
15. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87:2764-9.
16. Stefan N, Stumvoll M. Adiponectin-its role in metabolism and beyond. Horm Metab Res 2002;34:469-74.
17. World Health Organization. The ICD-10 classification of mental and behavioral disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Press; 1994.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
20. Yokoyama H, Hirose H, Ohgo H, Saito I. Associations among lifestyle status, serum adiponectin level and insulin resistance. Intern Med 2004;43:453-7.
21. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Toward a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. Polycystic ovary syndrome. Boston: Blackwell Scientific Publications; 1992:377-84.
22. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Task force on the phenotype of the polycystic ovary syndrome of the Androgen Excess and PCOS society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009;91:456-88.
23. Duisin D, Nikolić-Balkoski G, Batinić B. Sociodemographic profile of transsexual patients. Psychiatr Danub 2009;21:220-3.
24. Dittmann RW, Kappes ME, Kappes MH. Sexual behavior in adolescent and adult females with congenital adrenal hyperplasia. Psychoneuroendocrinology 1992;17:153-70.
25. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: A developmental aetiology for polycystic ovary syndrome? Hum Reprod 2005;11:357-74.
26. Garcia-Falgueras A, Swaab DF. A sex difference in the hypothalamic uncinate nucleus: Relationship to gender identity. Brain 2008;131:3132-46.
27. Legro RS. Pregnancy considerations in women with polycystic ovary syndrome. Clin Obstet Gynecol 2007;50:295-304.
28. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006;66:2081-6.
29. Vardi Y, Wylie KR, Moser C, Assalian P, Dean J, Asscheman H. Is physical examination required before prescribing hormones to patients with gender dysphoria? J Sex Med 2008;5:21-6.
30. Iimura O. Insulin resistance and hypertension in Japanese. Hypertens Res 1996;19(1 suppl):S1-S8.
31. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003;14:561-6.
32. Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol 2008;284:38-45.
33. Berra M, Armillotta F, D'Emidio L, Costantino A, Martorana G, Pelusi G, Meriggiola MC. Testosterone decreases adiponectin levels in female to male transsexuals. Asian J Androl 2006;8:725-9.
34. Resmini E, Andraghetti G, Rebora A, Cordera R, Vera L, Giusti M, Minuto F, Ferone D. Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments. J Androl 2008;29:580-5.
35. Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E, Bluher M, Kiess W. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004;89:4053-61.
36. Lanfranco F, Zitzmann M, Simoni M, Nieschlag E. Serum adiponectin levels in hypogonadal males: Influence of testosterone replacement therapy. Clin Endocrinol 2004;60:500-7.
37. Cupisti S, Giltay EJ, Gooren LJ, Kronawitter D, Oppelt PG, Beckmann MW, Dittrich R, Mueller A. The impact of testosterone administration to female-to-male transsexuals on insulin resistance and lipid parameters compared with women with polycystic ovary syndrome. Fertil Steril 2010;94:2647-53.
38. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-7.
39. Traish AM, Gooren LJ. Safety of physiological testosterone therapy in women: Lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758-64.
40. Perrone AM, Cerpolini S, Maria Salfi NC, Ceccarelli C, De Giorgi LB, Formelli G, Casadio P, Ghi T, Pelusi G, Pelusi C, Meriggiola MC. Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals. J Sex Med 2009;6:3193-200.
41. Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effects of sex steroid use on cardiovascular risk in transsexual individuals: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2010;72:1-10.